Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ARROWHEAD PHARMACEUTICALS, INC. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters valued at approximately $429.0 million (effective 2024-01-02).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters
- Value
- approximately $429.0 million
- Effective
- 2024-01-02
Exact text from the filing
On January 2, 2024, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to issue and sell 15,790,000 shares of the Company’s common stock (the “Shares”), par value $0.001 per share at an offering price of $28.50 per Share (the “Offering”).
View on SEC.gov